UNSPSC 51432606: Eplerenone

This classification denotes a steroid compound and antihypertensive agent with the molecular formula C24H30O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6995V82D0B, chemically known as 9,11alpha-epoxy-17-hydroxy-3-oxo-17alpha-pregn-4-ene-7alpha,21-dicarboxylic acid, gamma-lactone, methyl ester but generally known as eplerenone, which bears US NIH Compound Identifier 150310. European Medicines Agency schedules Eplerenone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06574MIG.

UNSPSC 51432606 Eplerenone, a Commodity code, represents state and local procurement of specific pharmaceutical products for emergency medical services, institutional health programs, and cooperative purchasing networks. State and local governments buy branded and generic medications through this code primarily to supply fire rescue departments, public health systems, and multi-jurisdictional pharmacy benefit programs. The soliciting bodies include municipal purchasing departments (fire rescue services), state health and human services agencies, and cooperative purchasing alliances spanning multiple states and their political subdivisions. Work being solicited ranges from single-medication emergency life support drug procurement—such as Tampa Fire Rescue's acquisition of advanced cardiac life support medications—to large-scale cooperative purchasing frameworks in which state agencies aggregate demand across participating jurisdictions to negotiate volume pricing with manufacturers and wholesalers.

Recent activity appears concentrated in the Southeast and Upper Midwest. The City of Tampa's Purchasing Department issued an Invitation for Bid (IFB) for Advanced Life Support Medications (26P00188) with a response deadline of April 8, 2026, and an estimated contract value of $40,000, requiring supply of four specific cardiac medications within ten calendar days of order with a nine-month minimum shelf life and one-year warranty; the contract includes a 5 percent bid discount for Small Local Business Enterprise participation. The Texas Health and Human Services Commission posted a Request for Information (RFI HHS0017013) in early April 2026 to gather vendor capabilities for a direct-to-manufacturer prescription program, signaling potential future state-level procurement but yielding no current award or budget figure. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (S1070000015802) with a March 26, 2026 response deadline to establish contracts for generic multi-source pharmaceuticals and OTC products across participating state and local facilities including Oregon; the RFP requires vendors to maintain relationships with three authorized wholesalers, achieve price competitiveness weighted at 75 percent of evaluation criteria, and comply with cGMP and Drug Supply Chain Security Act standards, with contract effectiveness set for July 1, 2026.